Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C. Boesteanu, Yan Wang, Roddy S. O’Connor, Wei‐Ting Hwang, Edward Pequignot, David E Ambrose, Changfeng Zhang, Nicholas S. Wilcox, Felipe Bedoya, Corin L. Dorfmeier, Chen Fang, Lifeng Tian, Harit Parakandi, Minnal Gupta, Regina M. Young, F. Brad Johnson, Irina Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, Megan M. Davis, Bruce L. Levine, Noelle V. Frey, Donald L. Siegel, Alexander C. Huang, E. John Wherry, Hans Bitter, Jennifer L. Brogdon, David L. Porter, Carl H. June, J. Joseph Melenhorst
Topics & Concepts
Chimeric antigen receptorCD8ImmunologyChronic lymphocytic leukemiaAntigenCytotoxic T cellT cellCancer researchBiologyCD19Immune systemLeukemiaMedicineIn vitroBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionT-cell and B-cell Immunology